Another Scandal in Evidence-Based Medicine: Ambulatory BP Monitoring Questioned?

Apparently, the scandal surrounding the EXCEL trial kicked the hornet’s nest as far as evidence-based medicine is concerned. This time, the stars were the actual authors of an article published in the prestigious New England Journal of Medicine (NEJM): the investigators retracted their paper due to issues in data analysis.

Otro “escándalo” en la medicina basada en la evidencia ¿El monitoreo ambulatorio de presión puesto en duda?

The aforementioned work was originally published in 2018 in the most prestigious medical journal worldwide, and it showed that ambulatory blood pressure monitoring readings were strongly associated with mortality. In that sense, the association was stronger than with readings obtained at the doctor’s office.

At the time, the lead author had mentioned that his work was the largest worldwide and provided unequivocal evidence that [ambulatory blood pressure monitoring] is superior to clinic pressure at predicting total and cardiovascular mortality. This week, the authors themselves retracted the article due to problems in statistical analyses.


Read also: Latest Guidelines “Dropped” After Scandal Over EXCEL Results.


Now, an independent statistical team is working with the aim of publishing the results as soon as possible.

The original suspicion was confirmed when researchers attempted to replicate findings in the International Database on Ambulatory Blood Pressure in Relation to Cardiovascular Outcomes.


Read also: Treating Both Atrial Valves Improves Survival.


Despite everything, ambulatory blood pressure monitoring is still the most suitable method to diagnose and manage hypertension.

2020-03-09-banegas2018 2020-03-09-nejmc2001445

Original title: Retraction: Relationship between clinic and ambulatory blood-pressure measurements a. nd mortality.

Reference: Banegas JR et al. N Engl J Med. 2020; Epub ahead of print.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

ACVC 2026 | CELEBRATE Trial: Prehospital Zalunfiban Use in STEMI

Optimizing antithrombotic therapy in the prehospital phase of ST-segment elevation myocardial infarction (STEMI) remains challenging due to the delayed onset of action of P2Y12...

Drugs for the Treatment of No-Reflow During PCI

The no-reflow phenomenon is one of the most frustrating complications of primary angioplasty (pPCI), reflecting persistent microvascular damage that, in the mid- to long-term,...

CRT 2026 | Clopidogrel vs Aspirin as Long-Term Monotherapy After Coronary Angioplasty

The use of aspirin as chronic antiplatelet therapy after percutaneous coronary intervention (PCI) has historically been the standard recommended by international guidelines. However, recent...

Low-Dose Rivaroxaban After Peripheral Angioplasty: Effectiveness and Safety in Real-World Clinical Practice

Following lower limb revascularization, optimal medical therapy includes antiplatelet agents, high-intensity statins, and control of cardiovascular risk factors. Recent studies such as COMPASS and...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Therapeutic strategies in carotid free-floating thrombus: evidence and controversies

Carotid free-floating thrombus (cFFT) is a rare entity with a high embolic risk, associated with acute neurological events such as stroke or transient ischemic...

The Two Sides of the Coin: What Do CHAMPION-AF and CLOSURE-AF Teach Us About Left Atrial Appendage Closure?

Letter to the editor: Juan Manuel Pérez Asorey Percutaneous left atrial appendage closure (LAAO) is currently going through one of the most interesting stages of...

CLOSURE-AF: Percutaneous Left Atrial Appendage Closure versus Medical Therapy in Atrial Fibrillation

Percutaneous left atrial appendage closure has been proposed as an alternative to anticoagulation in patients with atrial fibrillation and high bleeding risk; however, comparative...